

Edgar Filing: MEDICINES CO/ MA - Form 8-K

MEDICINES CO/ MA
Form 8-K
July 25, 2002

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 23, 2002

The Medicines Company

(Exact Name of Registrant as Specified in Charter)

Delaware	000-31191	04-3324394
-----	-----	-----
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

5 Sylvan Way, Suite 200 Parsippany, New Jersey	07054
-----	-----
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (973) 656-1616

(Former Name or Former Address, if Changed Since Last Report)

ITEM 5. OTHER EVENTS.

On July 23, 2002, The Medicines Company announced its financial results for the quarter and six month period ended June 30, 2002.

The full text of the press release issued in connection with the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

Edgar Filing: MEDICINES CO/ MA - Form 8-K

(c) Exhibits.

Exhibit No. -----	Description -----
99.1	Press release dated July 23, 2002 entitled "The Medicines Company Reports Second Quarter 2002 Financial Results and Confirms Annual Guidance."

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 25, 2002

THE MEDICINES COMPANY

By: /s/ Steven H. Koehler

Steven H. Koehler
Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No. -----	Description -----
99.1	Press release dated July 23, 2002 entitled "The Medicines Company Reports Second Quarter 2002 Financial Results and Confirms Annual Guidance."